NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis $8.38 -1.47 (-14.92%) Closing price 03:55 PM EasternExtended Trading$8.51 +0.13 (+1.50%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nanobiotix Stock (NASDAQ:NBTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nanobiotix alerts:Sign Up Key Stats Today's Range$8.37▼$8.9550-Day Range$4.38▼$10.0952-Week Range$2.76▼$10.59Volume27,034 shsAverage Volume12,040 shsMarket Capitalization$401.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company Overview Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. Read More Nanobiotix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreNBTX MarketRank™: Nanobiotix scored higher than 15% of companies evaluated by MarketBeat, and ranked 871st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingNanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNanobiotix has received no research coverage in the past 90 days.Read more about Nanobiotix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.Read more about Nanobiotix's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Nanobiotix has been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 209.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the float of Nanobiotix has been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 209.84%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News SentimentN/A News SentimentNanobiotix has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nanobiotix this week, compared to 1 article on an average week.Search Interest2 people have searched for NBTX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions.Read more about Nanobiotix's insider trading history. Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBTX Stock News HeadlinesGuggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)July 25, 2025 | theglobeandmail.comNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - MorningstarJuly 8, 2025 | morningstar.comM“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)July 7, 2025 | globenewswire.comNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ConferenceMay 28, 2025 | globenewswire.comNanobiotix Provides First Quarter 2025 Operational and Financial UpdateMay 21, 2025 | globenewswire.comNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 12, 2025 | globenewswire.comNanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further EvaluationMay 5, 2025 | finanznachrichten.deSee More Headlines NBTX Stock Analysis - Frequently Asked Questions How have NBTX shares performed this year? Nanobiotix's stock was trading at $2.87 at the beginning of the year. Since then, NBTX stock has increased by 205.9% and is now trading at $8.78. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO. How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nanobiotix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG). Company Calendar Today8/26/2025Next Earnings (Estimated)9/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBTX CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Nanobiotix$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside-8.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales-$11.61 million Price / Sales-36.26 Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-5.81Miscellaneous Outstanding Shares47,943,000Free Float46,289,000Market Cap$420.94 million OptionableNot Optionable Beta0.45 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:NBTX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.